About AbeXXa Biologics
AbeXXa Biologics is a company based in Lewes (United States) founded in 2015 by Jon Weidanz and Debra Weidanz was acquired by Boehringer Ingelheim in September 2021.. AbeXXa Biologics has raised $1.25 million across 1 funding round from investors including Boehringer Ingelheim. AbeXXa Biologics operates in a competitive market with competitors including Ultragenyx, Mereo BioPharma, Regeneron Pharmaceuticals, TScan Therapeutics and Lyell Immunopharma, among others.
- Headquarter Lewes, United States
- Founders Jon Weidanz, Debra Weidanz
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$1.25 M (USD)
in 1 rounds
-
Latest Funding Round
$1.25 M (USD), Seed
Sep 15, 2016
- Investors
-
Employee Count
Employee Count
-
Acquired by
Boehringer Ingelheim
(Sep 21, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of AbeXXa Biologics
AbeXXa Biologics has successfully raised a total of $1.25M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.25 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $1.2M
-
First Round
First Round
(15 Sep 2016)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2016 | Amount | Seed - AbeXXa Biologics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AbeXXa Biologics
AbeXXa Biologics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Boehringer Ingelheim. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Generic drugs and clinical research services are provided globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AbeXXa Biologics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - AbeXXa Biologics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Abexxa Biologics Comparisons
Competitors of AbeXXa Biologics
AbeXXa Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ultragenyx, Mereo BioPharma, Regeneron Pharmaceuticals, TScan Therapeutics and Lyell Immunopharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Abexxa Biologics
Frequently Asked Questions about AbeXXa Biologics
When was AbeXXa Biologics founded?
AbeXXa Biologics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Where is AbeXXa Biologics located?
AbeXXa Biologics is headquartered in Lewes, United States. It is registered at Lewes, Delaware, United States.
Who is the current CEO of AbeXXa Biologics?
Debra Weidanz is the current CEO of AbeXXa Biologics. They have also founded this company.
Is AbeXXa Biologics a funded company?
AbeXXa Biologics is a funded company, having raised a total of $1.25M across 1 funding round to date. The company's 1st funding round was a Seed of $1.25M, raised on Sep 15, 2016.
What does AbeXXa Biologics do?
AbeXXa Biologics was founded in 2015 and is headquartered in Lewes, United States. Operations are centered in the biotechnology sector, with a focus on advancing antibody-based therapeutics. Specific drug programs have not been disclosed as of October 2015. The company is led by co-founders Jon Weidanz and Debra Weidanz, who serves as CEO. Activities remain directed toward therapeutic development in biologics.
Who are the top competitors of AbeXXa Biologics?
AbeXXa Biologics's top competitors include Hummingbird Bioscience, Sutro Biopharma and Regeneron Pharmaceuticals.
Who are AbeXXa Biologics's investors?
AbeXXa Biologics has 1 investor. Key investors include Boehringer Ingelheim.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.